Home > Research > Publications & Outputs > Investigation of the human brain metabolome to ...

Links

Text available via DOI:

View graph of relations

Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease. / Graham, Stewart F.; Chevallier, Olivier P.; Roberts, Dominic et al.
In: Analytical Chemistry, Vol. 85, No. 3, 05.02.2013, p. 1803-1811.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Graham, SF, Chevallier, OP, Roberts, D, Hölscher, C, Elliott, CT & Green, BD 2013, 'Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease', Analytical Chemistry, vol. 85, no. 3, pp. 1803-1811. https://doi.org/10.1021/ac303163f

APA

Graham, S. F., Chevallier, O. P., Roberts, D., Hölscher, C., Elliott, C. T., & Green, B. D. (2013). Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease. Analytical Chemistry, 85(3), 1803-1811. https://doi.org/10.1021/ac303163f

Vancouver

Graham SF, Chevallier OP, Roberts D, Hölscher C, Elliott CT, Green BD. Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease. Analytical Chemistry. 2013 Feb 5;85(3):1803-1811. doi: 10.1021/ac303163f

Author

Graham, Stewart F. ; Chevallier, Olivier P. ; Roberts, Dominic et al. / Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease. In: Analytical Chemistry. 2013 ; Vol. 85, No. 3. pp. 1803-1811.

Bibtex

@article{8310cb4c535048578ecb6a017fa62d7b,
title = "Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease",
abstract = "A study combining high resolution mass spectrometry (liquid chromatography-quadrupole time-of-flight-mass spectrometry, UPLC-QTof-MS) and chemometrics for the analysis of post-mortem brain tissue from subjects with Alzheimer's disease (AD) (n = 15) and healthy age-matched controls (n = 15) was undertaken. The huge potential of this metabolomics approach for distinguishing AD cases is underlined by the correct prediction of disease status in 94-97% of cases. Predictive power was confirmed in a blind test set of 60 samples, reaching 100% diagnostic accuracy. The approach also indicated compounds significantly altered in concentration following the onset of human AD. Using orthogonal partial least-squares discriminant analysis (OPLS-DA), a multivariate model was created for both modes of acquisition explaining the maximum amount of variation between sample groups (Positive Mode-R2 = 97%; Q2 = 93%; root mean squared error of validation (RMSEV) = 13%; Negative Mode-R2 = 99%; Q2 = 92%; RMSEV = 15%). In brain extracts, 1264 and 1457 ions of interest were detected for the different modes of acquisition (positive and negative, respectively). Incorporation of gender into the model increased predictive accuracy and decreased RMSEV values. High resolution UPLC-QTof-MS has not previously been employed to biochemically profile post-mortem brain tissue, and the novel methods described and validated herein prove its potential for making new discoveries related to the etiology, pathophysiology, and treatment of degenerative brain disorders.",
author = "Graham, {Stewart F.} and Chevallier, {Olivier P.} and Dominic Roberts and Christian H{\"o}lscher and Elliott, {Christopher T.} and Green, {Brian D.}",
year = "2013",
month = feb,
day = "5",
doi = "10.1021/ac303163f",
language = "English",
volume = "85",
pages = "1803--1811",
journal = "Analytical Chemistry",
issn = "0003-2700",
publisher = "American Chemical Society",
number = "3",

}

RIS

TY - JOUR

T1 - Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease

AU - Graham, Stewart F.

AU - Chevallier, Olivier P.

AU - Roberts, Dominic

AU - Hölscher, Christian

AU - Elliott, Christopher T.

AU - Green, Brian D.

PY - 2013/2/5

Y1 - 2013/2/5

N2 - A study combining high resolution mass spectrometry (liquid chromatography-quadrupole time-of-flight-mass spectrometry, UPLC-QTof-MS) and chemometrics for the analysis of post-mortem brain tissue from subjects with Alzheimer's disease (AD) (n = 15) and healthy age-matched controls (n = 15) was undertaken. The huge potential of this metabolomics approach for distinguishing AD cases is underlined by the correct prediction of disease status in 94-97% of cases. Predictive power was confirmed in a blind test set of 60 samples, reaching 100% diagnostic accuracy. The approach also indicated compounds significantly altered in concentration following the onset of human AD. Using orthogonal partial least-squares discriminant analysis (OPLS-DA), a multivariate model was created for both modes of acquisition explaining the maximum amount of variation between sample groups (Positive Mode-R2 = 97%; Q2 = 93%; root mean squared error of validation (RMSEV) = 13%; Negative Mode-R2 = 99%; Q2 = 92%; RMSEV = 15%). In brain extracts, 1264 and 1457 ions of interest were detected for the different modes of acquisition (positive and negative, respectively). Incorporation of gender into the model increased predictive accuracy and decreased RMSEV values. High resolution UPLC-QTof-MS has not previously been employed to biochemically profile post-mortem brain tissue, and the novel methods described and validated herein prove its potential for making new discoveries related to the etiology, pathophysiology, and treatment of degenerative brain disorders.

AB - A study combining high resolution mass spectrometry (liquid chromatography-quadrupole time-of-flight-mass spectrometry, UPLC-QTof-MS) and chemometrics for the analysis of post-mortem brain tissue from subjects with Alzheimer's disease (AD) (n = 15) and healthy age-matched controls (n = 15) was undertaken. The huge potential of this metabolomics approach for distinguishing AD cases is underlined by the correct prediction of disease status in 94-97% of cases. Predictive power was confirmed in a blind test set of 60 samples, reaching 100% diagnostic accuracy. The approach also indicated compounds significantly altered in concentration following the onset of human AD. Using orthogonal partial least-squares discriminant analysis (OPLS-DA), a multivariate model was created for both modes of acquisition explaining the maximum amount of variation between sample groups (Positive Mode-R2 = 97%; Q2 = 93%; root mean squared error of validation (RMSEV) = 13%; Negative Mode-R2 = 99%; Q2 = 92%; RMSEV = 15%). In brain extracts, 1264 and 1457 ions of interest were detected for the different modes of acquisition (positive and negative, respectively). Incorporation of gender into the model increased predictive accuracy and decreased RMSEV values. High resolution UPLC-QTof-MS has not previously been employed to biochemically profile post-mortem brain tissue, and the novel methods described and validated herein prove its potential for making new discoveries related to the etiology, pathophysiology, and treatment of degenerative brain disorders.

U2 - 10.1021/ac303163f

DO - 10.1021/ac303163f

M3 - Journal article

C2 - 23252551

VL - 85

SP - 1803

EP - 1811

JO - Analytical Chemistry

JF - Analytical Chemistry

SN - 0003-2700

IS - 3

ER -